FDA committee votes in favor of Darzalex Faspro for HR-SMM
A U.S. Food and Drug Administration (FDA) committee has voted in favor of Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat high-risk smoldering multiple myeloma…
Myeloma
The unspoken weight of becoming a caregiver
I’ll never forget the day that my mother was diagnosed with myeloma. That was when the word “son” was entirely erased from my identity.
Cell therapy anito-cel extends treatment-resistant RRMM survival
Nearly all the people with relapsed or refractory multiple myeloma (RRMM) who took part in a Phase 2 clinical trial responded to the cell…
IGI’s relapsed/refractory multiple myeloma drug wins fast track status
The U.S. Food and Drug Administration (FDA) has granted fast track status to ISB 2001, an experimental therapy for difficult-to-treat multiple myeloma. The designation…
Linvoseltamab, now Lynozyfic, earns EU’s conditional OK to treat RRMM
The European Commission (EC) has conditionally approved Regeneron Pharmaceuticals’ linvoseltamab, now Lynozyfic, to treat adults with relapsed or refractory multiple myeloma (RRMM).
Trial data for 2 Caribou CAR T-cell therapies due this year
Caribou Biosciences is reprioritizing its pipeline to focus on two of its CAR T-cell therapies for blood cancer, including one, CB-011, that’s being developed…
Blenrep combos approved in UK as multiple myeloma treatment
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Blenrep (belantamab mafodotin) in combination with other medications for hard-to-treat multiple myeloma. The…
Europe extends Darzalex approval as multiple myeloma treatment
The European Commission has extended its approval of Johnson & Johnson’s Darzalex (daratumumab) for injection under the skin as part of a quadruple regimen…
Exercise program boosts life quality in newly diagnosed patients: Trial
Getting regular exercise can help improve life quality, ease depression, and minimize the risk of medication side effects in people with newly diagnosed multiple…
CAR T-cell therapy successfully treats myeloma in Hong Kong
A CAR T-cell therapy manufactured in mainland China has been successfully deployed for the first time in Hong Kong to treat a man with myeloma,…
